Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas

Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas

Patients with non-Hodgkin lymphoma (NHL) are treated today with a cocktail of drugs referred to as CHOP (Cyclophosphamide, Hydroxyldaunorubicin, Oncovin, and Prednisone). Subsets of patients with NHL of germinal center origin bear oncogenic mutations in the EZH2 histone methyltransferase. Clinical t...

Full description

Bibliographic Details
Main Authors: Knutson, Sarah K., Warholic, Natalie M., Johnston, L. Danielle, Klaus, Christine R., Wigle, Tim J., Iwanowicz, Dorothy, Littlefield, Bruce A., Porter-Scott, Margaret, Smith, Jesse J., Moyer, Mikel P., Copeland, Robert A., Pollock, Roy M., Kuntz, Kevin W., Raimondi, Alejandra, Keilhack, Heike
Format: Online
Language:English
Published: Public Library of Science 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4262195/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4262195/

Similar Items